Table 6.
Subgroup analysis of proportions of patients without preemptive therapy at 14 and 24 weeks (effectiveness analysis set; N = 670)
| Baseline characteristics | Classification | 14 weeks | 24 weeks | |||
|---|---|---|---|---|---|---|
| n | n (%)a | P-value | n (%)a | P-value | ||
| Overall | – | 670 | 559 (83.43) | 485 (73.39) | ||
| Sex | Male | 394 | 321 (81.47) | 0.114b | 286 (72.59) | 0.930b |
| Female | 276 | 238 (86.23) | 199 (72.10) | |||
| Age | 15–64 years | 567 | 470 (82.89) | 0.478c | 415 (73.19) | 0.348c |
| ≥ 65 years | 92 | 79 (85.87) | 63 (68.48) | |||
| Unknown | 11 | 10 (90.91) | 7 (63.64) | |||
| Body weight | < 45 kg | 59 | 50 (84.75) | 0.856b | 42 (71.19) | 0.879b |
| ≥ 45 kg | 603 | 502 (83.25) | 436 (72.31) | |||
| Unknown | 8 | 7 (87.50) | 7 (87.50) | |||
| Recipient CMV antibody status | Negative | 74 | 72 (97.30) | < 0.001b | 70 (94.59) | < 0.001b |
| Positive | 557 | 454 (81.51) | 386 (69.30) | |||
| Untested | 26 | 21 (80.77) | 18 (69.23) | |||
| Unknown | 13 | 12 (92.31) | 11 (84.62) | |||
| Donor CMV antibody status | Negative | 267 | 223 (83.52) | 1.000b | 184 (68.91) | 0.081b |
| Positive | 267 | 224 (83.90) | 203 (76.03) | |||
| Untested | 116 | 97 (83.62) | 84 (72.41) | |||
| Unknown | 20 | 15 (75.00) | 14 (70.00) | |||
| Recipient/donor CMV antibody status | R+/D− | 235 | 193 (82.13) | 0.036d | 155 (65.96) | < 0.001d |
| R+/D+ | 222 | 183 (82.43) | 164 (73.87) | |||
| R−/D+ | 33 | 32 (96.97) | 31 (93.94) | |||
| R−/D− | 29 | 28 (96.55) | 27 (93.10) | |||
| Unknown | 151 | 123 (81.46) | 108 (71.52) | |||
| HLA compatibility | HLA matched | 204 | 187 (91.67) | < 0.001d | 167 (81.86) | 0.001d |
| HLA mismatched | 359 | 286 (79.67) | 241 (67.13) | |||
| Haploidentical | 84 | 64 (76.19) | 56 (66.67) | |||
| Unknown | 23 | 22 (95.65) | 21 (91.30) | |||
| HSCT donor source | Bone marrow | 222 | 187 (84.23) | 0.851d | 162 (72.97) | 0.442d |
| Peripheral blood | 204 | 171 (83.82) | 153 (75.00) | |||
| Umbilical cord blood | 244 | 201 (82.38) | 170 (69.67) | |||
| Acute post-transplant GVHD | Yes | 345 | 274 (79.42) | 230 (66.67) | ||
| No | 290 | 253 (87.24) | 0.011b | 225 (77.59) | 0.003b | |
| Unevaluable | 22 | 20 (90.91) | 19 (86.36) | |||
| Unknown | 13 | 12 (92.31) | 11 (84.62) | |||
| Chronic post-transplant GVHD | Yes | 118 | 92 (77.97) | 67 (56.78) | ||
| No | 433 | 361 (83.37) | 0.176b | 316 (72.98) | 0.001b | |
| Unevaluable | 105 | 94 (89.52) | 91 (86.67) | |||
| Unknown | 14 | 12 (85.71) | 11 (78.57) | |||
| Engraftment | Yes | 626 | 516 (82.43) | 444 (70.93) | ||
| No | 32 | 32 (100.00) | 0.006b | 31 (96.88) | < 0.001b | |
| Unknown or unstated | 12 | 11 (91.67) | 10 (83.33) | |||
| Comorbidities | Yes | 311 | 245 (78.78) | 205 (65.92) | ||
| No | 359 | 314 (87.47) | 0.003b | 280 (77.99) | < 0.001b | |
| Corticosteroid administration | No | 360 | 304 (84.44) | 0.467b | 272 (75.56) | 0.056b |
| Yes | 310 | 255 (82.26) | 213 (68.71) | |||
CMV cytomegalovirus, D donor, GVHD graft versus host disease, HLA human leukocyte antigen, R recipient
P < 0.05 indicates a statistically significant difference
aNumber of patients who did not receive preemptive therapy until week 14 or 24, and percentage of patients in each category with the total number of patients in each category as the denominator
bFisher’s exact test
cWilcoxon rank-sum test
dChi-square test